TickerTalks
Browse all tickers →
TickerTalks›$GILD
GIGILD

Gilead Sciences, Inc.

$GILD·$187B·Drug Manufacturers - General·Healthcare
$147.92-1.7%YTD+20.8%1Y+25.1%
Price updated 15h ago·X counts updated 3d ago
GIGILD
$GILDGilead Sciences, Inc.
$147.92-1.67%202 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $GILD on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

202X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $GILD's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 74% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-09

Gilead is being called a top biopharma acquirer of 2026 (behind only Lilly), and holders speculate $KYTX has already priced in a Gilead takeout (Gilead was a founding investor and still owns ~7.9%). A daily flag pattern is setting up a $150 breakout toward $155+ ATH, and $150 calls are approaching 150% gainers.

Read what X is saying about $GILD

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $GILD — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-10-02

The move is getting stronger, with heavier trading behind it.

Gilead at 80% of 52-week range — top biopharma acquirer behind Lilly, lenacapavir ramp doing the P&L work.

Gilead Sciences is the global HIV-and-virology leader — Biktarvy, lenacapavir (Sunlenca and now the twice-yearly PrEP), plus a growing oncology franchise. The stock is up 20% YTD and 80% of its 52-week range on operational acceleration and M&A positioning.

  • The P&L is firm: revenue grew 4.4% YoY to $6.96B last quarter at a 38% operating margin and 79% gross margin — HIV franchise is the cash engine, and the twice-yearly lenacapavir PrEP launch is the specific long-tail growth leg.
  • Gilead being called a top biopharma acquirer of 2026 (behind only Lilly) is a specific M&A positioning signal — holders speculate $KYTX has already priced in a Gilead takeout (Gilead was a founding investor and owns ~7.9%); the forward M&A pipeline is a real catalyst.
  • Insider Dickinson's $436K sale at $145.29 is modest; the broader insider pattern is routine, with a daily flag setting up a $150 breakout toward $155+ ATH.

Accelerating holds while the lenacapavir PrEP launch extends and M&A positioning continues to generate pipeline optionality. A soft Oct 29 earnings print on HIV revenue, or any specific commentary on PrEP uptake softening, is what cools the move; a signed M&A acquisition (KYTX or other oncology-biotech target) is what extends the breakout toward prior cycle highs.

Agrees with X sentimentX bulls on the top-biopharma-acquirer-of-2026 framing, the $KYTX takeout speculation (Gilead owns ~7.9%), the $150 breakout toward $155+ ATH, and $150 calls approaching 150% gainers have the specific thesis right — this is a quality compounder with M&A optionality.

What to watch: Oct 29 earnings — HIV franchise revenue growth, lenacapavir PrEP uptake, FY27 revenue guide, and any specific M&A commentary. A soft HIV print or PrEP miss is what cools the breakout.

On the calendar: 2026-10-29 — Q3 FY26 earnings

Read the AI verdict on $GILD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells Biktarvy for HIV, Veklury for COVID, and Trodelvy for oncology; large-cap specialty pharma with antiviral and cancer drug focus.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $GILD.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $GILD

Neutral — Sells Biktarvy for HIV, Veklury for COVID, and Trodelvy for oncology; large-cap specialty pharma with antiviral and cancer drug focus.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+32.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
17.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
20.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
38.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
42.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-6.75$-7.25+6.9%
Q1 2026May 7, 2026$2.03$1.91+6.3%
Q4 2025Feb 10, 2026$1.86$1.81+2.8%
Q3 2025Oct 30, 2025$2.47$2.13+16.0%
Next earningsThu, Oct 29·consensus EPS $2.17

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.0B+4.4%79.2%37.2%$1.63$2.4B
Q4 FY25$7.9B+4.7%79.5%37.7%$1.76$3.1B
Q3 FY25$7.8B+3.0%79.8%42.8%$2.46$4.0B
Q2 FY25$7.1B+1.8%78.8%34.9%$1.57$720.0M

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$30.7B$30.5B – $31.0B-$0.43-$0.58 – -$0.2919
FY27$32.8B$31.7B – $33.4B$9.96$9.41 – $11.5018
FY28$34.5B$32.3B – $37.5B$10.71$9.19 – $12.2321
FY29$37.0B$36.0B – $38.2B$12.11$11.68 – $12.6010
FY30$39.2B$38.1B – $40.4B$13.17$12.71 – $13.7110

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.78%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+1.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.335-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 1O'day Daniel PatrickCEO15.0K sh$2.2MSellSep 15Andrew D DickinsonCFO3.0K sh$436KSellSep 15Johanna MercierChief Comm & Corp Aff Officer3.0K sh$433KSellSep 1O'day Daniel PatrickCEO15.0K sh$2.2MSellAug 26Anthony WeltersDirector18.0K sh$2.7MSellAug 20Jeffrey BluestoneDirector5.0K sh$725KSellAug 17Andrew D DickinsonCFO3.0K sh$415KSellAug 17Johanna MercierChief Comm & Corp Aff Officer28.0K sh$3.9MSellAug 3O'day Daniel PatrickCEO14.4K sh$1.9MSellJul 15Andrew D DickinsonCFO3.0K sh$390K
1–10 of 18
+ 37 other (16 exempts · 13 inkinds · 8 awards) in window

See when $GILD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 7SC 13D/A
AI summary

the Reporting Person on July 17, 2020, as amended by Amendmen amended its 13D filing disclosing a beneficial ownership position of a 5%+ stake in GILD (GILD) as of 2026-08-07. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

S-3ASRAuto-shelf registrationAug 6S-3ASR
AI summary

Gilead Sciences, Inc. filed a new automatic shelf registration (S-3ASR) on August 6, 2026, registering an unspecified amount of debt securities, common stock, preferred stock, depositary shares, warrants, subscription rights, stock purchase contracts, and stock purchase units for issuance on a delayed or continuous basis. As a large accelerated filer, the S-3ASR becomes effective upon filing. No offering size or specific transaction is disclosed; this is a routine shelf refresh establishing the legal framework for future capital markets activity. Actual dilution or debt issuance would occur only upon a separate prospectus supplement.

SC 13D/AActivist amendmentMay 27SC 13D/A
AI summary

With filed Amendment No. 4 to Schedule 13D disclosing updated beneficial ownership in GILD (GILD). The filing covers approximately 4,977,089 shares of GILD. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.

8-KMaterial agreementMay 208-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Gilead Sciences, Inc. (GILD) filed an 8-K on May 14, 2026 disclosing a material definitive agreement (Item 1.01), creation of a direct financial obligation (Item 2.03), and an other-event disclosure (Item 8.01). Gilead is a Foster City, California-based biopharmaceutical company focused on HIV, hepatitis, and oncology listed on Nasdaq. Filed concurrently with Gilead's $3B debt offering (424B5), Items 1.01 and 2.03 likely reflect the indenture for that debt issuance; this is a significant capital market event for the large-cap biopharma company.

424B5Prospectus supplement (offering)May 18424B5
AI summary

Gilead Sciences, Inc. (GILD) priced a $3 billion four-tranche senior notes offering on May 18, 2026, comprising: $500M 4.250% Notes due May 20, 2028; $1B 4.400% Notes due May 20, 2029; $1B 4.600% Notes due May 20, 2031; and $500M 4.900% Notes due May 20, 2034. Interest is payable semi-annually on May 20 and November 20 each year starting November 2026. This is a large investment-grade debt capital markets transaction for Gilead; proceeds are likely for general corporate purposes, which may include funding pipeline acquisitions or licensing deals given Gilead's active M&A history.

424B5Prospectus supplement (offering)May 14424B5
AI summary

Gilead Sciences, Inc. (GILD) filed a preliminary 424B5 on May 14, 2026 for a multi-tranche senior notes offering with all pricing terms blank (amounts, rates, and maturities pending final terms). This preliminary filing precedes the final 424B5 pricing on May 18, 2026 which established the $3B four-tranche deal. The blank terms confirm this is the preliminary prospectus supplement and the actual deal economics were determined the following day.

8-KShareholder voteMay 48-K — Item 5.07: Shareholder vote
AI summary

Gilead Sciences Inc. (GILD) filed an 8-K reporting results of its annual shareholders' meeting under Item 5.07. Shareholders voted on standard governance matters including election of directors, ratification of the independent auditor, and advisory votes on executive compensation. All management-supported proposals passed as expected at the major pharmaceutical company. Detailed vote tallies by proposal are included in the filing.

SC 13D/AActivist amendmentApr 28SC 13D/A
AI summary

Gilead Sciences Inc. (GILD) received an amended Schedule 13D/A (Amendment No. 1) in connection with its ownership of Arcellx Inc. shares, where Gilead holds more than 5% and files as an active rather than passive holder. This amendment updates Gilead's beneficial ownership position in the oncology biotech following prior transactions. As a strategic investor with collaboration arrangements, Gilead filed under the more active 13D rather than passive 13G form. The filing discloses current share counts and updated purpose of the investment.

+ 12 other (2 10-Qs · 2 earnings 8-Ks · 2 13Fs · 2 SC TO-T/As) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?fool.com·3d agoHead to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)defenseworld.net·3d agoBetter Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharmafool.com·4d agoGilead Sciences (GILD) Laps the Stock Market: Here's Whyzacks.com·5d agoGilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plandefenseworld.net·10d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$NVO$PFE$JNJ$ABBV$MRK$BMY
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport